- How to scientifically select a new molecular entities (NMEs) in a research leads portfolio
- How to characterize physico-chemical properties as function of the expected Target Product Profile (TPP)
- Rationally select polymorphism before development
- How and when do you need to utilize enabling technologies to streamline drug development of molecule presenting limitations/weaknesses.
Philippe Lienard, CMC Discovery Coordinator, Sanofi